<DOC>
	<DOCNO>NCT00008125</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I trial study effectiveness gemcitabine combine docetaxel carboplatin without filgrastim treat patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Filgrastim Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose gemcitabine docetaxel administer carboplatin without filgrastim ( G-CSF ) patient advance solid tumor . II . Determine safe dose level schedule regimen phase II study patient . III . Determine toxicity regimen patient . OUTLINE : This dose-escalation study docetaxel gemcitabine . Patients receive gemcitabine IV 30 minute , docetaxel IV 1 hour , carboplatin IV 30 minute day 1 . Patients also receive gemcitabine IV 30 minute day 8 . Treatment repeat every 21 day approximately 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . If DLT grade 4 neutropenia , filgrastim ( G-CSF ) add regimen ( administer subcutaneously day 2-7 8-14 blood count recover ) . A new MTD determine . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor curative therapy exist No symptomatic uncontrolled brain leptomeningeal metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST great 1.5 time ULN Renal : Creatinine great ULN Cardiovascular : No unstable cardiac disease require treatment No new onset crescendo rest angina Stable exertion angina allow Other : Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method contraception least 1 week prior study , study , least 2 week study No symptomatic peripheral neuropathy great grade 1 No significant neurologic psychiatric disorder include psychotic disorder , dementia , seizures No significant medical psychiatric condition would preclude study No active infection No malignancy within past 5 year except nonmelanoma skin cancer , carcinoma situ cervix , cancer , due stage , highly unlikely recur treatment No known hypersensitivity E. coliderived product PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic hematopoietic growth factor ( i.e. , filgrastim ( GCSF ) sargramostim ( GMCSF ) ) Chemotherapy : No 1 prior chemotherapy regimen advance disease At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Prior cisplatin , carboplatin , docetaxel , paclitaxel , gemcitabine allow No concurrent chemotherapy Endocrine therapy : At least 3 week since prior hormonal therapy recover Radiotherapy : At least 3 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : At least 3 week since prior investigational drug recover No concurrent experimental agent No concurrent anticancer therapy No concurrent prophylactic oral IV antibiotic without fever present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>